Profile data is unavailable for this security.
About the company
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
- Revenue in CAD (TTM)0.00
- Net income in CAD-27.64m
- Incorporated1998
- Employees29.00
- LocationOncolytics Biotech Inc1167 Kensington Cres Nw Suite 210Calgary Alberta Canada T2n 1X7CALGARY T2R 0C5CanadaCAN
- Phone+1 (403) 670-7377
- Fax+1 (403) 283-0858
- Websitehttps://www.oncolyticsbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYUS Life Sciences Corp | 428.00k | -36.83m | 55.77m | 2.00 | -- | 3.42 | -- | 130.30 | -0.5247 | -0.5247 | 0.0061 | 0.2192 | 0.0074 | 0.075 | 0.5757 | -- | -63.34 | -57.88 | -88.37 | -71.19 | 46.50 | -16.16 | -8,604.67 | -10,367.37 | 0.1593 | -35.94 | 0.3955 | -- | 17.79 | 213.99 | -72.73 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -28.53m | 88.44m | 12.00 | -- | 4.30 | -- | -- | -0.2528 | -0.2528 | 0.00 | 0.1816 | 0.00 | -- | -- | 0.00 | -78.28 | -107.22 | -85.23 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
| MustGrow Biologics Corp | 4.71m | -423.96k | 90.38m | 0.00 | -- | 25.09 | -- | 19.18 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -27.64m | 107.85m | 29.00 | -- | 11.91 | -- | -- | -0.3644 | -0.3644 | 0.00 | 0.1175 | 0.00 | -- | -- | -- | -78.58 | -81.99 | -104.96 | -97.25 | -- | -- | -- | -- | -- | -- | 0.1051 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Medicenna Therapeutics Corp | 0.00 | -26.68m | 114.65m | 16.00 | -- | 5.76 | -- | -- | -0.3747 | -0.3747 | 0.00 | 0.2603 | 0.00 | -- | -- | 0.00 | -87.95 | -54.93 | -98.62 | -60.91 | -- | -- | -- | -- | -- | -2.20 | 0.0087 | -- | -- | -- | -153.44 | -- | -- | -- |
| NervGen Pharma Corp | 0.00 | -24.01m | 157.49m | 10.00 | -- | 17.13 | -- | -- | -0.37 | -0.37 | 0.00 | 0.1308 | 0.00 | -- | -- | -- | -123.68 | -121.15 | -332.31 | -180.20 | -- | -- | -- | -- | -- | -22.89 | 0.0139 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
| Holder | Shares | % Held |
|---|---|---|
| International Assets Investment Management LLCas of 30 Jun 2024 | 198.40k | 0.26% |
| Seeds Investor LLCas of 30 Sep 2024 | 189.94k | 0.25% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2024 | 85.00k | 0.11% |
| Citadel Securities LLCas of 30 Sep 2024 | 79.25k | 0.10% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2024 | 74.50k | 0.10% |
| Commonwealth Equity Services LLCas of 30 Sep 2024 | 61.11k | 0.08% |
| CIBC World Markets, Inc.as of 30 Sep 2024 | 57.84k | 0.08% |
| Geode Capital Management LLCas of 30 Sep 2024 | 41.94k | 0.05% |
| Long Focus Capital Management LLCas of 30 Sep 2024 | 40.00k | 0.05% |
| BBVA Asset Management SA SGIICas of 30 Jun 2024 | 30.02k | 0.04% |
